Somewhat Positive Press Coverage Somewhat Unlikely to Impact Medovex Corp. (NASDAQ:MDVX) Stock Price
Press coverage about Medovex Corp. (NASDAQ:MDVX) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Medovex Corp. earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.5993185952518 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Medovex Corp. (NASDAQ:MDVX) traded up 1.67% during midday trading on Friday, hitting $0.85. 52,919 shares of the company were exchanged. The stock’s 50-day moving average is $0.91 and its 200-day moving average is $1.15. Medovex Corp. has a one year low of $0.79 and a one year high of $1.82. The stock’s market cap is $16.14 million.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-medovex-corp-nasdaqmdvx-stock-price.html.
In other Medovex Corp. news, Director Steve Gorlin acquired 30,000 shares of Medovex Corp. stock in a transaction dated Wednesday, June 7th. The stock was bought at an average cost of $0.96 per share, with a total value of $28,800.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have bought a total of 95,989 shares of company stock valued at $88,750 over the last ninety days. 25.10% of the stock is owned by insiders.
About Medovex Corp.
MedoveX Corporation, through its subsidiaries, focuses on developing medical devices primarily in the United States and Europe. It offers DenerveX device, a disposable single-use kit for the treatment of various medical applications, including pain relief. The company serves healthcare providers, physicians, and third-party payors.
Receive News & Ratings for Medovex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medovex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.